Analysis of RCAS1 immunoreactivity within hydatidiform mole cells and decidual cells according to the applied therapeutic strategy: surgery or surgery followed by chemotherapy

Gynecol Obstet Invest. 2012;73(2):106-12. doi: 10.1159/000328509. Epub 2012 Jan 24.

Abstract

Introduction: Trophoblast cells cooperate with both maternal immune cells and decidual cells to help develop the suppressive microenvironment of the endometrium. The maternal immune response against hydatidiform mole depends on this suppressive endometrial profile. Since RCAS1 is one of the molecular factors participating in the development of the suppressive profile of the endometrium we decided to examine the immunoreactivity of the RCAS1 within both the trophoblast and decidual cells during the development of hydatidiform mole.

Methods: We analyzed the immunoreactivity of RCAS1 on both trophoblast and decidual cells derived from patients who underwent curettage because of hydatidiform mole. These patients were then divided into two subgroups according to whether or not they required chemotherapy after the surgical procedure.

Result: We observed significantly lower immunoreactivity levels of both RCAS1 within the complete molar lesions of the patients on whom surgery alone was performed when compared to the levels found in those for whom surgery was followed by chemotherapy.

Conclusion: RCAS1 staining may provide information regarding the intensity of the immunosuppressive microenvironment of both the molar lesion and the endometrium. This information can prove significant in determining the clinical course of hydatidiform mole.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm / immunology*
  • Chemotherapy, Adjuvant
  • Decidua / drug effects
  • Decidua / immunology*
  • Female
  • Humans
  • Hydatidiform Mole / drug therapy
  • Hydatidiform Mole / immunology*
  • Hydatidiform Mole / surgery
  • Hydatidiform Mole / therapy*
  • Immunohistochemistry
  • Pregnancy
  • Pregnancy Complications, Neoplastic
  • Uterine Neoplasms / drug therapy
  • Uterine Neoplasms / immunology*
  • Uterine Neoplasms / surgery
  • Uterine Neoplasms / therapy*

Substances

  • Antigens, Neoplasm
  • EBAG9 protein, human